Supporting evidence

• LedgerSolid quarter based on: Significant R&D tax refund received · Advancement to Phase 3 pivotal trial for ATH434 · Positive clinical data for ATH434 in MSA.
• EventR&D Tax Refund Received
• EventPhase 3 Trial Initiation Planned

• EventPositive Clinical Data Reported
• EventThis refund provides important funding for the continued development of Alterity’s clinical programs, including the Phase 3 pivotal trial for ATH434, bolstering the company's finan…
• EventThis confirmation validates the registrational pathway for ATH434, reducing regulatory uncertainty and paving the way for a single pivotal Phase 3 trial, which is critical for pote…
• EventIncreases visibility and scientific validation for ATH434 within the neurology community.
• InitiativeFDA minutes confirm the registrational pathway and protocol details, indicating good progress towards initiation.
• InitiativeActivities are on track to initiate by year-end 2026, following confirmation of the registrational pathway by the FDA.
• InitiativeFunds from the Australian Government's R&D tax incentive for 2025 have been received, providing financial support.
• InitiativePeer-reviewed study published demonstrating utility of QSM as a biomarker for MSA, supporting earlier diagnosis and assessment of iron-modulating therapies like ATH434.